ArticleFrontiers in immunology2020
A T Cell Receptor Sequencing-Based Assay Identifies Cross-Reactive Recall CD8
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.Cancer immunology research · 2026Trial
- CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses.The Journal of clinical investigation · 2022Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Regulated cell death-induced coagulation dysfunction in sepsis.Journal of thrombosis and thrombolysis · 2026Review
- replicateFest: An R Package and Shiny App for Analysis of T Cell Receptor Repertoire Data from the Functional Expansion.bioRxiv : the preprint server for biology · 2026Article
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- AI-driven computational methods and benchmarking for T-cell antigen identification.Briefings in bioinformatics · 2026Review
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.Nature communications · 2026Article
- Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells.Cell systems · 2025Article
- ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer.Journal for immunotherapy of cancer · 2025Article
- The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.Frontiers in immunology · 2025Article
- Circulating immune landscape and immune signatures in spontaneous HIV controllers.Frontiers in immunology · 2025Observational
- Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4Cell reports. Medicine · 2024Article
- Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.The Journal of clinical investigation · 2023Article
- The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.Molecular cancer · 2023Review
- T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Insights into anti-tumor immunityFrontiers in immunology · 2023Review
- SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection.EBioMedicine · 2022Article
- The importance of taking ART appropriately in children and adolescents with HIV-1 to reach the highest capacity of immune function later in life.Frontiers in immunology · 2022Article
- Functional impairment of HIV-specific CD8Immunity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
HIV-1 positive elite controllers or suppressors control viral replication without antiretroviral therapy, likely via CTL-mediated elimination of infected cells, and therefore represent a model of an HIV-1 functional cure. Efforts to cure HIV-1 accordingly rely on the existence or generation of antigen-specific cytotoxic T lymphocytes (CTL) to eradicate infected cells upon reversal of latency. Detecting and quantifying these HIV-1-specific CTL responses will be crucial for developing vaccine and T cell-based immunotherapies. A recently developed assay, called MANAFEST, uses T cell receptor (TCR) Vβ sequencing of peptide-stimulated cultures followed by a bioinformatic pipeline to identify neoantigen-specific T cells in cancer patients. This assay is more sensitive than conventional immune assays and therefore has the possibility to identify HIV-1 antigenic targets that have not been previously explored for vaccine or T cell immunotherapeutic strategies. Here we show that a modified version of the MANAFEST assay, called ViraFEST, can identify memory CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.